Clinical Trial

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-31.
Trial Details
NCT Number NCT06536868
Lead Sponsor Second Hospital of Shanxi Medical University
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 40 participants
Start Date 2024-08-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-24